Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7013053 | 0.90 | ALDH1A1 (0.50) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL10181023 | 0.84 | CYP1A2 (0.53) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL5092353 | 0.82 | CYP1A2 (0.57) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL577637 | 0.80 | POLB (0.53) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL984078 | 0.80 | CYP1A2 (0.50) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL8404026 | 0.80 | ALDH1A1 (0.64) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL668838 | 0.79 | KDM4E (0.69) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL30501799 | 0.77 | ALDH1A1 (0.50) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL12883191 | 0.77 | CYP1A2 (0.47) | KDM4EALDH1A1LMNATDP1CYP1A2 | |
| SCHEMBL31229375 | 0.77 | TDP1 (0.64) | KDM4EALDH1A1LMNATDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| EP-4452964-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| CN-118339153-A | Heteroaromatic compounds for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023117681-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| CN-109641854-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | Recordati Industria Chimica e Farmacentica S.p.A. (IT) | 2022-09-13 | — | — | US | disclosed |
| EP-0353640-B2 | Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE GMBH (DE) | 2003-10-15 | — | — | EP | disclosed |
| EP-0592680-B1 | N-sulfonated carboxamide derivatives as fungicides for plants | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5536837-A | PLANT FUNGICIDES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5478799-A | Herbicide for weeds and fungicide for crops | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| US-5444060-A | Applying to control pathogenic fungi | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0353640-B1 | Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators | HOECHST SCHERING AGREVO GMBH (DE) | 1995-04-12 | — | — | EP | disclosed |
| EP-0592680-A1 | N-SULFONYLATED, SIX-MEMBERED NITROGENOUS AROMATIC CARBOXAMIDE DERIVATIVE OR SALT THEREOF, PRODUCTION THEREOF, AND PEST CONTROL AGENT | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1994-04-20 | — | — | EP | disclosed |
| US-5186736-A | Pre- and postemergence | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-02-16 | — | — | US | disclosed |
| US-5053072-A | HETEROCYCLIC N-ACYLSULFONAMIDES, AND THEIR USE AS HERBICIDES OR GROWTH REGULATORS | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-01 | — | — | US | disclosed |
| EP-0353640-A2 | Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators | Hoechst Schering AgrEvo GmbH (DE) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | KDM4E 2708/4885ALDH1A1 3426/4885LMNA 2852/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KDM4E 4646/4885ALDH1A1 3433/4885LMNA 3376/4885 |
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | GRM5, GRIK5, GRM2 | KDM4E 1087/4885ALDH1A1 3850/4885LMNA 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.